Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Preferred Name | Anagrelide Hydrochloride | |
| Synonyms |
|
|
| Definitions |
The hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C183131 |
|
| CAS_Registry |
823178-43-4
|
|
| code |
C183131
|
|
| Contributing_Source |
FDA
|
|
| definition |
The hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)
|
|
| FDA_UNII_Code |
YTM763Y5C8
|
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset | ||
| label |
Anagrelide Hydrochloride
|
|
| Legacy Concept Name |
Anagrelide_Hydrochloride
|
|
| NCI_META_CUI |
CL1771366
|
|
| Preferred_Name |
Anagrelide Hydrochloride
|
|
| prefixIRI |
NCIT:C183131
|
|
| prefLabel |
Anagrelide Hydrochloride
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping